2023
Tau epicenter identification and connectivity in clinically heterogeneous Alzheimer’s disease variants
Trainer A, Xu W, Chase A, O'Dell R, Tun S, Li J, Ju S, van Dyck C, Mecca A, Fredricks C. Tau epicenter identification and connectivity in clinically heterogeneous Alzheimer’s disease variants. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079435.Peer-Reviewed Original ResearchAmnestic Alzheimer's diseaseLogopenic variant primary progressive aphasiaPosterior cortical atrophyFunctional connectivity mapsHigher tau burdenFunctional connectivityTau burdenAlzheimer's diseaseConnectivity mapsLongitudinal tau-PETSpread of tauVariant primary progressive aphasiaFusiform gyrusFrontal eye fieldPrimary progressive aphasiaBrains of participantsTau PET scansSuperior parietal lobulePatient-specific biomarkersCortical atrophyCommon subtypeTau-PETHealthy controlsParietooccipital cortexPET scans
2022
Aging of the brain in bipolar disorder: Illness- and onset-related effects in cortical thickness and subcortical gray matter volume
Villa L, Colic L, Kim J, Sankar A, Goldman D, Lessing B, Pittman B, Alexopoulos G, van Dyck C, Blumberg H. Aging of the brain in bipolar disorder: Illness- and onset-related effects in cortical thickness and subcortical gray matter volume. Journal Of Affective Disorders 2022, 323: 875-883. PMID: 36526112, PMCID: PMC9839524, DOI: 10.1016/j.jad.2022.12.026.Peer-Reviewed Original ResearchConceptsGray matter volumeOccipital cortical thicknessSubcortical gray matter volumesCortical thicknessBipolar disorderMatter volumeOlder adultsOnset of BDIndividuals age 40Striatal gray matter volumeGray matter reductionsOnset bipolar disorderGray matter decreasesPrefrontal cortical thicknessStructural brain differencesHigh suicide riskCross-sectional designHealthy controlsCognitive dysfunctionTreatment resistanceAge 40Striatal volumeSevere symptomsSuicide attempt historySuicide attemptsHypothalamic Functional Connectivity and Apathy in People with Alzheimer’s Disease and Cognitively Normal Healthy Controls
Chaudhary S, Zhornitsky S, Chao H, van Dyck C, Li C. Hypothalamic Functional Connectivity and Apathy in People with Alzheimer’s Disease and Cognitively Normal Healthy Controls. Journal Of Alzheimer's Disease 2022, 90: 1615-1628. PMID: 36314209, PMCID: PMC10064487, DOI: 10.3233/jad-220708.Peer-Reviewed Original ResearchConceptsMiddle temporal gyrusMild cognitive impairmentMotivation circuitsFunctional connectivityPath analysisWhole-brain regressionPCu/PCCState functional connectivityTotal scoreTemporal gyrusNeural markersCingulate cortexMemory dysfunctionRSFCHealthy controlsCognitive statusCognitive impairmentAlzheimer's diseaseApathyPrecuneusMemoryRsFCsDepressionScale total scoreCognitive subscores
2017
Cholinergic activity and levodopa‐induced dyskinesia: a multitracer molecular imaging study
Brumberg J, Küsters S, Al‐Momani E, Marotta G, Cosgrove KP, van Dyck C, Herrmann K, Homola GA, Pezzoli G, Buck AK, Volkmann J, Samnick S, Isaias IU. Cholinergic activity and levodopa‐induced dyskinesia: a multitracer molecular imaging study. Annals Of Clinical And Translational Neurology 2017, 4: 632-639. PMID: 28904985, PMCID: PMC5590520, DOI: 10.1002/acn3.438.Peer-Reviewed Original ResearchLevodopa-induced dyskinesiaNicotinic acetylcholine receptorsSingle photon emissionNondyskinetic patientsDisease patientsCholinergic activityHealthy controlsAcetylcholine receptorsRegional cerebral metabolic activityDeoxyglucose positron emission tomographyExpression of dyskinesiaCerebral metabolic activityStriatal cholinergic activityParkinson's disease patientsBasal ganglia structuresStriatal binding potentialPositron emission tomographyDopaminergic responsivenessAffected sideClinical variablesDyskinetic subjectsCholinergic signalingGanglia structuresMolecular imaging studiesNeuronal excitability
2001
The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans
Martinez D, Gelernter J, Abi-Dargham A, van Dyck C, Kegeles L, Innis R, Laruelle M. The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans. Neuropsychopharmacology 2001, 24: 553-560. PMID: 11282255, DOI: 10.1016/s0893-133x(00)00216-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmphetamineAttention Deficit Disorder with HyperactivityBenzamidesCarrier ProteinsCocaineCocaine-Related DisordersDopamineDopamine AntagonistsDopamine Plasma Membrane Transport ProteinsGenotypeHumansIodine RadioisotopesMembrane GlycoproteinsMembrane Transport ProteinsMinisatellite RepeatsNeostriatumNerve Tissue ProteinsPhenotypePolymorphism, GeneticPsychotic DisordersPyrrolidinesRadiopharmaceuticalsSchizophreniaTomography, Emission-Computed, Single-PhotonConceptsAmphetamine-induced dopamine releaseDopamine releaseDAT expressionDopamine transporterDifferent patient populationsAttention deficit hyperactivity disorderDeficit hyperactivity disorderNeurochemical phenotypePatient populationHealthy controlsDAT densityComputerized emission tomographyDopamine transmissionClinical phenotypeDiagnostic groupsSignificant associationEmission tomographyCocaine-induced paranoiaHyperactivity disorderTandem repeat polymorphismVNTR polymorphismDopamine transporter geneRepeat polymorphismTotal sample
1997
The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer’s disease
van Dyck C, Lin C, Robinson R, Cellar J, Smith E, Nelson J, Arnsten A, Hoffer P. The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer’s disease. Psychopharmacology 1997, 132: 217-226. PMID: 9292621, DOI: 10.1007/s002130050339.Peer-Reviewed Original ResearchConceptsRegional cerebral blood flowParietal regional cerebral blood flowCerebral blood flowAlzheimer's diseaseAD patientsBlood flowDouble-blind trialWeeks of treatmentAD drug therapyProbable Alzheimer's diseaseParietal association cortexSingle photon emissionPlacebo TIDRCBF abnormalitiesCholinergic drugsDrug therapyHealthy controlsRCBF ratiosPharmacological interventionsHealthy subjectsAssociation cortexPatientsLinopirdineBrain regionsNeuropsychological function